REPORTS

Let’s Pullulate and Expand Your Business

RNAi for Therapeutic Market - Global Professional Analysis and Forecast to 2026

Dec 18, 2019  |  215 PAGES  |  REPORT CODE: CMM256605
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide RNAi for Therapeutic market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.9% during the forecast period.

This report presents the market size and development trends by detailing the RNAi for Therapeutic market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the RNAi for Therapeutic market will be shown in this report. In short, this report will comprehensively reveal the characteristics of RNAi for Therapeutic industry and will help you to build a panoramic view of the industrial development.

RNAi for Therapeutic Market, By Type:

  • siRNA

  • miRNA

  • shRNA

RNAi for Therapeutic Market, By Application:

  • Cancer

  • Cardiovascular

  • HBV

  • Others

Some of the leading players are as follows:

  • Mirna Therapeutics

  • Arrowhead

  • Sirnaomics

  • Dicerna Pharmaceuticals

  • Alnylam Pharmaceuticals

  • Gradalis

  • miRagen Therapeutics

  • RXi Pharmaceuticals

  • Quark Pharmaceuticals

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 RNAi for Therapeutic Market: Technology Type Analysis

  • 4.1 RNAi for Therapeutic Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 RNAi for Therapeutic Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 siRNA

    • 4.3.2 miRNA

    • 4.3.3 shRNA

5 RNAi for Therapeutic Market: Product Analysis

  • 5.1 RNAi for Therapeutic Product Market Share Analysis, 2018 & 2026

  • 5.2 RNAi for Therapeutic Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 RNAi for Therapeutic Market: Application Analysis

  • 6.1 RNAi for Therapeutic Application Market Share Analysis, 2018 & 2026

  • 6.2 RNAi for Therapeutic Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Cancer

    • 6.3.2 Cardiovascular

    • 6.3.3 HBV

    • 6.3.4 Others

7 RNAi for Therapeutic Market: Regional Analysis

  • 7.1 RNAi for Therapeutic Regional Market Share Analysis, 2018 & 2026

  • 7.2 RNAi for Therapeutic Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Mirna Therapeutics

    • 9.1.1 Mirna Therapeutics Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Arrowhead

    • 9.2.1 Arrowhead Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Sirnaomics

    • 9.3.1 Sirnaomics Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Dicerna Pharmaceuticals

    • 9.4.1 Dicerna Pharmaceuticals Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Alnylam Pharmaceuticals

    • 9.5.1 Alnylam Pharmaceuticals Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Gradalis

    • 9.6.1 Gradalis Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 miRagen Therapeutics

    • 9.7.1 miRagen Therapeutics Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 RXi Pharmaceuticals

    • 9.8.1 RXi Pharmaceuticals Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Quark Pharmaceuticals

    • 9.9.1 Quark Pharmaceuticals Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

 

The List of Tables and Figures (Totals 83 Figures and 140 Tables)

  • Figure siRNA RNAi for Therapeutic market, 2015 - 2026 (USD Million)

  • Figure miRNA RNAi for Therapeutic market, 2015 - 2026 (USD Million)

  • Figure shRNA RNAi for Therapeutic market, 2015 - 2026 (USD Million)

  • Figure Cancer market, 2015 - 2026 (USD Million)

  • Figure Cardiovascular market, 2015 - 2026 (USD Million)

  • Figure HBV market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America RNAi for Therapeutic market, by country, 2015 - 2026 (USD Million)

  • Table North America RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table North America RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table North America RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table U.S. RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table U.S. RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Canada RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Canada RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Europe RNAi for Therapeutic market, by country, 2015 - 2026 (USD Million)

  • Table Europe RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Europe RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Europe RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table U.K. RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table U.K. RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Germany RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Germany RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table France RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table France RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Italy RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Italy RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Spain RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Spain RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific RNAi for Therapeutic market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table China RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table China RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Japan RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Japan RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table India RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table India RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Latin America RNAi for Therapeutic market, by country, 2015 - 2026 (USD Million)

  • Table Latin America RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Latin America RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Latin America RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Brazil RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Brazil RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Mexico RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Mexico RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Argentina RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Argentina RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table MEA RNAi for Therapeutic market, by country, 2015 - 2026 (USD Million)

  • Table MEA RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table MEA RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table MEA RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table South Africa RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table South Africa RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria RNAi for Therapeutic market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria RNAi for Therapeutic market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria RNAi for Therapeutic market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Mirna Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Arrowhead Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sirnaomics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Dicerna Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Alnylam Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Gradalis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table miRagen Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table RXi Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Quark Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top